Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV 550 in Acute Adenovirus Keratoconjunctivitis
NCT01156025Phase 2Completed
- Sponsor
- Laboratoires Théa
- Start
- Mar 2009
- Primary completion
- Feb 2010
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in adenoviral keratoconjunctivitis (EKC) comparing GV550 with Placebo (2 arms). Primary endpoint: Efficacy of GV550. Started Mar 2009; status: completed.
02
Drugs
tertomotide
03
Conditions
adenoviral keratoconjunctivitis (EKC)
Beyond the preview
Go deeper on NCT01156025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01156025.